Steven Cohen Axsome Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 542,620 shares of AXSM stock, worth $49.2 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

542,620

Previous 479,044 13.27%

Holding current value

$49.2 Million

Previous $38.6 Million 26.43%

% of portfolio

0.13%

Previous 0.11%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $5.02 Million - $6.09 Million	63,576 Added 13.27%	542,620 $48.8 Million
Q2 2024 Aug 14, 2024	BUY	$65.72 - $80.5 $6.58 Million - $8.06 Million	100,180 Added 26.44%	479,044 $38.6 Million
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $31.8 Million - $44.8 Million	-458,337 Reduced 54.75%	378,864 $30.2 Million
Q4 2023 Feb 14, 2024	BUY	$57.42 - $83.61 $17.5 Million - $25.5 Million	305,264 Added 57.39%	837,201 $66.6 Million
Q3 2023 Nov 14, 2023	BUY	$69.25 - $82.21 $4.43 Million - $5.26 Million	63,934 Added 13.66%	531,937 $37.2 Million
Q2 2023 Aug 14, 2023	SELL	$58.41 - $90.35 $41 Million - $63.4 Million	-701,824 Reduced 59.99%	468,003 $33.6 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $30.3 Million - $39 Million	519,762 Added 79.96%	1,169,827 $72.2 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $1.28 Million - $2.56 Million	32,165 Added 5.21%	650,065 $50.1 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $20.8 Million - $40.2 Million	576,125 Added 1379.11%	617,900 $27.6 Million
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $908,188 - $1.95 Million	41,775 New	41,775 $1.6 Million
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $2.14 Million - $3.11 Million	-42,300 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$55.91 - $81.44 $1.97 Million - $2.87 Million	-35,200 Reduced 45.42%	42,300 $2.4 Million
Q4 2020 Feb 16, 2021	SELL	$66.31 - $86.52 $872,440 - $1.14 Million	-13,157 Reduced 14.51%	77,500 $6.31 Million
Q3 2020 Nov 16, 2020	SELL	$68.34 - $85.84 $11.5 Million - $14.5 Million	-168,740 Reduced 65.05%	90,657 $6.46 Million
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $21.2 Million - $41.9 Million	-424,857 Reduced 62.09%	259,397 $21.3 Million
Q1 2020 May 15, 2020	BUY	$41.2 - $101.31 $28.2 Million - $69.3 Million	684,254 New	684,254 $40.3 Million
Q4 2019 Feb 14, 2020	SELL	$16.71 - $106.24 $2.67 Million - $17 Million	-160,000 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$20.24 - $29.16 $3.24 Million - $4.67 Million	160,000 New	160,000 $3.24 Million
Q1 2019 May 15, 2019	SELL	$2.63 - $16.34 $657,500 - $4.09 Million	-250,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.0 - $4.15 $500,000 - $1.04 Million	250,000 New	250,000 $705,000

Others Institutions Holding AXSM

# of Institutions

325

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account